Products for Research Use Only

BCR-ABL-IN-6

CAT: 0804-HY-150569Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-150569Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BCR-ABL-IN-6 (9h) is a selective Bcr-Abl kinase inhibitor with IC50s of 4.6 and 227 nM for Bcr-AblWT and Bcr-AblT3151 respectively. BCR-ABL-IN-6 inhibits Bcr-Abl kinase with strong affinity inside the cells with an EC50 of 14.6 nM. BCR-ABL-IN-6 is an imatinib derivative which can be used for research of chronic myelogenous leukemia[1]. BCR-ABL-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
CAS Number
2499499-26-0
UNSPSC
12352005
Target
Bcr-Abl
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bcr-abl-in-6.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC=CC(C#CC2=CC=CC3=C2C(N)=NN3)=C1)C4=CC=C(N5CCOCC5)C(C(F)(F)F)=C4
Molecular Formula
C27H22F3N5O2
Molecular Weight
505.49
References & Citations
[1]El-Damasy AK, et al. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity[J]. European Journal of Medicinal Chemistry, 2020, 207:112710.|[2]El-Damasy AK, et al. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity[J]. European Journal of Medicinal Chemistry, 2020, 207:112710.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products